Maintenance Regorafenib Significantly Delays Disease Progression After First-Line Treatment in Patients with Advanced Non-Adipocytic Soft Tissue Sarcomas By Ogkologos - April 28, 2025 768 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the EREMISS study Source RELATED ARTICLESMORE FROM AUTHOR Quadruplet Isa-KRd Regimen Improves NGS-MRD Negativity in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma EMA Recommends Granting a Marketing Authorisation for Tarlatamab Transdermal Oestradiol Patches Non-inferior to LHRH Agonists Regarding Metastasis-Free Survival in Patients with Locally Advanced Prostate Cancer MOST POPULAR Long-Term Benefit of Nivolumab Plus Low-Dose Ipilimumab in Previously Treated Patients... June 30, 2022 FDA Approves Toripalimab-tpzi for Nasopharyngeal Carcinoma November 13, 2023 ctDNA Detection After Initial Treatment of Early-Stage NSCLC Has Potential to... April 1, 2022 Air Pollution and Breast Cancer Risk – A Link That Calls... October 17, 2023 Load more HOT NEWS Second Interim Analysis Shows OS Improvement with Adjuvant Olaparib for Germline... A College Senior vs. A Global Pandemic ESMO Sarcoma and Rare Cancers Congress 2025, Lugano, Switzerland, 20-22 March Cuando necesita ayuda con responsabilidades de cuidado
